• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dimopoulos M, Wang M, Maisnar V, et al. Response, progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018, 11(1):49. doi: 10.1186/s13045-018-0583-7.

home / authors / dimopoulos-m-wang-m-maisnar-v-et-al-response

Articles

© 2024 MJH Life Sciences
AJMC®
All rights reserved.